Skip to search formSkip to main contentSkip to account menu

Biosimilar Pharmaceuticals

Known as: Biosimilar Pharmaceuticals [Chemical/Ingredient], Pharmaceuticals, Biosimilar 
BIOLOGIC PRODUCTS that are imitations but not exact replicas of innovator products.
National Institutes of Health

Related topics

Related topics

5 relations

Broader (1)

Biosimilars
In Bloodaspects of radiation effectschemical synthesisstandards characteristics

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Analytical Similarity of a Proposed Biosimilar BVZ-BC to Bevacizumab.
BVZ-BC (Bevacizumab-Biosimilar Candidate) is a proposed biosimilar to bevacizumab. Bevacizumab binds to vascular endothelial… 
2019
2019
A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects
.
OBJECTIVE To compare the pharmacokinetic (PK) profiles, immunogenicity, and safety of the proposed biosimilar IBI305 with those… 
2019
2019
Capture of biologic and biosimilar dispensings in a consortium of U.S.‐based claims databases: Utilization of national drug codes and Healthcare Common Procedure Coding System modifiers in medical…
To assess the capture of biologics (originator and biosimilar) in the Biologics and Biosimilars Collective Intelligence… 
2018
2018
Implementing a treatment registry for a biosimilar: continuous safety surveillance of the biosimilar Bevax® (bevacizumab) in Argentina
2017
2017
Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan
Background Biosimilar granulocyte colony-stimulating factor (G-CSF) has recently been introduced into clinical practice. G-CSFs… 
2016
2016
Möglichkeiten und Herausforderungen der Extrapolation bei Biosimilars
Zusammenfassung Obwohl sich die bisher in der Europäischen Union zugelassenen Biosimilars als sicher und effektiv erwiesen haben… 
2016
2016
Biosimilars in der Onkologie: Eine therapeutische Alternative zu Referenzarzneimitteln?
Zusammenfassung Biosimilare Arzneimittel (Biosimilars) sind seit zehn Jahren in Europa verfügbar und werden u. a. auch in der… 
Review
2015
Review
2015
Biosimilars in der Rheumatologie
  • Dr. R. Alten
  • Zeitschrift für Rheumatologie (Print)
  • 2015
  • Corpus ID: 115231922
ZusammenfassungHintergrundIn diesem Artikel wird das Design klinischer Studien im Rahmen der Entwicklung von Biosimilars in… 
2014
2014
Structural and functional analyses of biosimilar enoxaparins available in Brazil
Summary Biosimilar enoxaparins have been available for clinical use in Brazil since 2009. Although their use has reduced costs of… 
2013
2013
Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors
The human recombinant G-CSF filgrastim has been widely used for the mobilization of CD34+ stem cells of healthy donors (HD). In… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)